智飞生物：子公司吸附无细胞百白破（组分）联合疫苗（成人及青少年用）临床试验获批

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biological Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of an acellular combined vaccine for adults and adolescents, aimed at preventing infections caused by diphtheria, tetanus, and whooping cough [1] Group 1 - The vaccine is designed to prevent infectious diseases caused by diphtheria, tetanus, and whooping cough [1] - The approval allows the company to initiate clinical trials for the vaccine [1]